Positioning biologics in the treatment of IBD: A practical guide – Which mechanism of action for whom?
The number of available biological therapies have doubled over the last 10 years and the arrival of novel molecules (interleukin 23p19 inhibitors) is ongoing alongside the development of small molecules. As a result of this vast landscape of treatment, positioning advanced therapies (according to cl...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-01-01
|
| Series: | Current Research in Pharmacology and Drug Discovery |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2590257122000244 |
| _version_ | 1811200888663965696 |
|---|---|
| author | Pascal Juillerat Maude Martinho Grueber Roseline Ruetsch Giulia Santi Marianne Vuillèmoz Pierre Michetti |
| author_facet | Pascal Juillerat Maude Martinho Grueber Roseline Ruetsch Giulia Santi Marianne Vuillèmoz Pierre Michetti |
| author_sort | Pascal Juillerat |
| collection | DOAJ |
| description | The number of available biological therapies have doubled over the last 10 years and the arrival of novel molecules (interleukin 23p19 inhibitors) is ongoing alongside the development of small molecules. As a result of this vast landscape of treatment, positioning advanced therapies (according to clinical situation, efficacy and safety) is of paramount importance to providing personalized, appropriate IBD treatment.In this publication the recent available literature is summarized for practical integration into clinical practice including comparative efficacy data, patient and disease demographics. We refer to recent publications and expert opinion in order to facilitate the decision making process of positioning biologicals IBD treatment. |
| first_indexed | 2024-04-12T02:11:18Z |
| format | Article |
| id | doaj.art-7a848fd9bcaf49a1882ef497d849659d |
| institution | Directory Open Access Journal |
| issn | 2590-2571 |
| language | English |
| last_indexed | 2024-04-12T02:11:18Z |
| publishDate | 2022-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Current Research in Pharmacology and Drug Discovery |
| spelling | doaj.art-7a848fd9bcaf49a1882ef497d849659d2022-12-22T03:52:23ZengElsevierCurrent Research in Pharmacology and Drug Discovery2590-25712022-01-013100104Positioning biologics in the treatment of IBD: A practical guide – Which mechanism of action for whom?Pascal Juillerat0Maude Martinho Grueber1Roseline Ruetsch2Giulia Santi3Marianne Vuillèmoz4Pierre Michetti5Gastroenterology, Clinic for Visceral Surgery and Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland; Crohn and Colitis Center, Gastro-entérologie Beaulieu SA, Lausanne, Switzerland; Corresponding author. Clinic for Visceral Surgery and Medicine Inselspital, Bern University Hospital Freiburgstrasse 10, CH-3010, Bern, Switzerland.Gastroenterology, Clinic for Visceral Surgery and Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland; Crohn and Colitis Center, Gastro-entérologie Beaulieu SA, Lausanne, SwitzerlandCrohn and Colitis Center, Gastro-entérologie Beaulieu SA, Lausanne, SwitzerlandGastroenterology, Clinic for Visceral Surgery and Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, SwitzerlandCrohn and Colitis Center, Gastro-entérologie Beaulieu SA, Lausanne, SwitzerlandCrohn and Colitis Center, Gastro-entérologie Beaulieu SA, Lausanne, Switzerland; Division of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, SwitzerlandThe number of available biological therapies have doubled over the last 10 years and the arrival of novel molecules (interleukin 23p19 inhibitors) is ongoing alongside the development of small molecules. As a result of this vast landscape of treatment, positioning advanced therapies (according to clinical situation, efficacy and safety) is of paramount importance to providing personalized, appropriate IBD treatment.In this publication the recent available literature is summarized for practical integration into clinical practice including comparative efficacy data, patient and disease demographics. We refer to recent publications and expert opinion in order to facilitate the decision making process of positioning biologicals IBD treatment.http://www.sciencedirect.com/science/article/pii/S2590257122000244Biological therapyMonoclonal antibodiesInfliximabAdalimumabVedolizumabUstekinumab |
| spellingShingle | Pascal Juillerat Maude Martinho Grueber Roseline Ruetsch Giulia Santi Marianne Vuillèmoz Pierre Michetti Positioning biologics in the treatment of IBD: A practical guide – Which mechanism of action for whom? Current Research in Pharmacology and Drug Discovery Biological therapy Monoclonal antibodies Infliximab Adalimumab Vedolizumab Ustekinumab |
| title | Positioning biologics in the treatment of IBD: A practical guide – Which mechanism of action for whom? |
| title_full | Positioning biologics in the treatment of IBD: A practical guide – Which mechanism of action for whom? |
| title_fullStr | Positioning biologics in the treatment of IBD: A practical guide – Which mechanism of action for whom? |
| title_full_unstemmed | Positioning biologics in the treatment of IBD: A practical guide – Which mechanism of action for whom? |
| title_short | Positioning biologics in the treatment of IBD: A practical guide – Which mechanism of action for whom? |
| title_sort | positioning biologics in the treatment of ibd a practical guide which mechanism of action for whom |
| topic | Biological therapy Monoclonal antibodies Infliximab Adalimumab Vedolizumab Ustekinumab |
| url | http://www.sciencedirect.com/science/article/pii/S2590257122000244 |
| work_keys_str_mv | AT pascaljuillerat positioningbiologicsinthetreatmentofibdapracticalguidewhichmechanismofactionforwhom AT maudemartinhogrueber positioningbiologicsinthetreatmentofibdapracticalguidewhichmechanismofactionforwhom AT roselineruetsch positioningbiologicsinthetreatmentofibdapracticalguidewhichmechanismofactionforwhom AT giuliasanti positioningbiologicsinthetreatmentofibdapracticalguidewhichmechanismofactionforwhom AT mariannevuillemoz positioningbiologicsinthetreatmentofibdapracticalguidewhichmechanismofactionforwhom AT pierremichetti positioningbiologicsinthetreatmentofibdapracticalguidewhichmechanismofactionforwhom |